Status:
TERMINATED
Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?
Lead Sponsor:
Medical University of Warsaw
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
This is prospective, observational study using point of care test to determine bio-ADM whole blood concentrations and its predictive value in patients with COVID-19 treated in the ICU.
Detailed Description
About 5% of all patients infected with the SARS-CoV-2 virus require treatment in the ICU. The main reason for admission to the ICU is acute hypoxemic respiratory failure, which in most cases is associ...
Eligibility Criteria
Inclusion
- age ≥ 18 years
- polymerase chain reaction (PCR) confirmed COVID-19
- severe stage of pneumonia caused by SARS-CoV-2 requiring oxygen therapy
- informed consent to participate in the study
Exclusion
- qualification to palliative care
- life expectancy \< 48 h
- mechanical ventilation at the beginning of the hospitalization
- transfer from other ICU
- pregnancy
Key Trial Info
Start Date :
March 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04813939
Start Date
March 22 2021
End Date
January 31 2022
Last Update
May 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Warsaw
Warsaw, Poland, 05-002